What does Novartis's pursuit of a label expansion for #Pluvicto possibly mean for patients and the field of radiopharmaceutical therapy? 🤔 Geoff Johnson, MD, PhD and Kathy Spencer-Pike discussed this exact question in our recent webinar. Watch it here 👉 https://hubs.ly/Q02LtZW90 #NuclearMedicine #Radiopharmaceuticals #CancerCare
Nucleus RadioPharma’s Post
More Relevant Posts
-
Great learning opportunity here
Join us in Bethesda, MD on Sept 19-21. Learn from the experts. Connect with colleagues. Gain invaluable insights. Explore the latest in radiopharmaceutical therapy. To learn more check out the Therapeutics Conference website here https://lnkd.in/eHK7vXgD
-
-
The field of drug development is constantly evolving. From new #cancer treatments to innovative therapies for liver and #neurological conditions, new advancements in #pharmaceuticals represent significant strides in #medical science. Discover more about the groundbreaking drugs from Astellas Pharma, Madrigal Pharmaceuticals, and Karuna Therapeutics (BMS) that are set to transform patient care in the coming years. Check out our complete report on the Healthark Insights website - https://lnkd.in/ehCi-ZQG #Pharmaceuticals #DrugApproval #MedicalInnovation #ClinicalResearch #NewTherapies #LifeSciences #FutureOfMedicine #PatientCare #FDAApproval
-
$MNPR - The results in both show near complete elimination of the tumor after a single injection of the radiopharmaceutical agent. These studies demonstrate the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients. https://lnkd.in/ethsdXBY
-
-
Learn how Calyx #MedicalImaging delivered critical imaging data in advance of deadlines on an expedited timeline to help a leading pharmaceutical company receive #Accelerated FDA approval for a #MultipleMyeloma treatment. https://lnkd.in/dt95ppBJ #ChooseCalyx #ClinicalTrials #Oncology Jason Xu #MyelomaActionMonth
-
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. Meet Lisata Therapeutics, Inc. @ #Sachs_OIF More Info @ https://lnkd.in/djZps36w #OncologyInnovation #CancerResearch #BiotechInvesting #PharmaTrends #HealthcareInnovation #OncologyForum #CancerTherapyAdvancements #BiopharmaDeals #SachsForum #ASCO2024 "
-
-
Learn how Calyx #MedicalImaging delivered critical imaging data in advance of deadlines on an expedited timeline to help a leading pharmaceutical company receive #Accelerated FDA approval for a #MultipleMyeloma treatment. https://lnkd.in/dmwCfmVt #ChooseCalyx #ClinicalTrials #Oncology Jason Xu #MyelomaActionMonth
-
Processa Pharmaceuticals shares jumped 26% or 35c to $1.70 per share after announcing that the first patient has been dosed in a Phase 2 clinical trial evaluating N... For daily news and analysis subscribe to the www.biopharmapeek.com newsletter.
Processa Pharmaceuticals jumps 28% after Phase 2 study update
tipranks.com
-
Tenosynovial Giant Cell Tumors Pipeline Insights and Analysis 2024: FDA Approvals, Therapies, MOA, ROA, and Developments | Deciphera Pharma, Elixiron Immunotherapeutics, Daiichi Sankyo, Abbisko Thera: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Tenosynovial Giant Cell Tumors pipeline constitutes 5+ key companies continuously working towards developing 5+ Tenosynovial Giant Cell Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Tenosynovial Giant Cell Tumors Pipeline Insights and Analysis 2024: FDA Approvals, Therapies, MOA, ROA, and Developments | Deciphera Pharma, Elixiron Immunotherapeutics, Daiichi Sankyo, Abbisko Thera | ABNewswire
-
Learn how Calyx #MedicalImaging delivered critical imaging data in advance of deadlines on an expedited timeline to help a leading pharmaceutical company receive #Accelerated FDA approval for a #MultipleMyeloma treatment. https://lnkd.in/eZ9RapBT #ChooseCalyx #ClinicalTrials #Oncology Jason Xu #MyelomaActionMonth
